Description
| Product Name | : | Ponaxen |
| Generic Name | : | Ponatinib |
| Formulation | : | Tablet |
| Available Pack Size | : | 60’s pot |
| Available Strength | : | 15 mg, 45mg |
| Registrations | : | Export Only |
Product Description:
Ponaxen (Ponatinib), is an oral drug under the generic of Ponatinib, for the first-line therapy of the people affected with chronic myelogenous leukemia.
It is a highly potential and multi-targeted third generation Bcr-Abl tyrosine-kinase inhibitors (TKI) which is indicated for the adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) or Ph+ALL for those who have no other TKI therapy.
It is also indicated for the adult patients with T315I-positive CML (chronic phase, accelerated phase of blast phase) or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL).
Reviews
There are no reviews yet.